PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1304163

PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1304163

Menstrual Cramps Treatment Market, By Drug Class, By Type, By Route of Administration, By Dosage Form, By Distribution Channel, and By Region - Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030

PUBLISHED: May 30, 2023

PAGES: 205 Pages

DELIVERY TIME: 2-3 business days

ADD TO COMPARE

SELECT AN OPTION

Description

Menstrual cramps (dysmenorrhea) are throbbing or cramping pains in the lower abdomen. Many women have menstrual cramps just before and during their menstrual periods. Conditions such as endometriosis or uterine fibroids can cause menstrual cramps. Symptoms occurred like aching pain in lower abdomen, a feeling of pressure in belly, pain in hips, lower back, and inner thighs. To treat menstrual cramps, over-the-counter pain relievers such as NSAID's like ibuprofen (Advil), Naproxen sodium (Aleve) are used. Hormonal antagonists drugs such as MYFEMBREE (Pfizer) also used for the treatment of menstrual cramps.

Market Dynamics

Market players in the market are focusing on ncreasing inorganic strategies such as collaboration for menstrual cramp treatment is expected to drive the the global menstrual cramp market growth over the forecast period. For instance, on April 10, 2018, AbbVie, a global research and development-based biopharmaceutical company, and Neurocrine Biosciences, announced PDUFA (Prescription Drug User Fee Act) for Elagolix in endometriosis-associated pain.. Elagolix is a gonadotropin-releasing hormone (GnRH) receptor antagonist. It is administered orally, and is a short-acting molecule that blocks endogenous GnRH receptors in the pituitary gland.

Increasing prevalence of menstrual cramps is expected to drive the market growth over the forecast period. For instance, on January 14, 2022, article published by MDPI, stated that a study was conducted in Europe's Romania in prospective, analytical, observational and took place between 7 November 2019 and 30 January 2020. This study included a population of 1720 from five university centers throughout the country. Out of 1,720 participants, 1,349 (78.4%) had dysmenorrhea. The prevalence of dysmenorrhea, ranging from 16% to 91% has been reported. The most widely used drugs were non-steroidal anti-inflammatory drugs, utilized by 741 students (54.9%) has been reported.

Moreover, according to article published by International Journal of Womens Health, a study was conducted in Southern Ethiopia, the prevalence of primary dysmenorrhea among all the female students is 70% of population who reported.

Key features of the study:

This report provides in-depth analysis of the global menstrual cramps treatment market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2023-2030), considering 2022 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global menstrual cramps treatment market based on the following parameters company highlights, products portfolio, key highlights, financial performance, and strategies.
Key companies covered as a part of this study include Pfizer Inc., Ingelheim International GmbH., Bayer AG, , Cipla Inc, Teva Pharmaceutical Industries Ltd., Sanofi, Johnson & Johnson Services, Inc., Dr. Reddy's Laboratories Ltd, Almatica Pharma LLC., F. Hoffmann-La Roche Ltd, GlaxoSmithKline Plc, Eisen Pharmaceutical Co. (Pvt.) Ltd., Emcure Pharmaceuticals, AbbVie., Sparsha Pharma International Pvt Ltd, Hope Medicine (Nanjing) Co., Ltd.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Global menstrual cramps treatments market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global menstrual cramps treatments market

Detailed Segmentation:

Global Menstrual Cramp Treatment Market, By Drug Class:
- Analgesics
- Anticholinergic
- Non-steroidal anti-inflammatory drugs (NSAIDs)
- Haematinics
- Others (Progestins, Among others)
Global Menstrual Cramp Treatment Market, By Type:
- Primary Dysmenorrhea
- Secondary Dysmenorrhea
Global Menstrual Cramp Treatment Market, By Route of Administration:
- Oral
- Injectable
- Topical
- Others (Intrauterine, Others)
Global Menstrual Cramp Treatment Market, By Dosage Form:
- Tablet
- Capsules
- Suspension
- Others (Transdermal Patch, Among others)
Global Menstrual Cramp Treatment Market, By Distribution channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Menstrual Cramps Treatment Market, By Region:
- North America
  - By Country:
- U.S.
- Canada
- Latin America
  - By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
  - By Country:
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
  - By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
  - By Country:
- GCC
- Israel
- Rest of Middle East
- Africa
  - By Country/Region:
- South Africa
- Central Africa
- North Africa
Company Profiles
- Pfizer Inc.*
  - Company Highlights
  - Products Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Ingelheim International GmbH PerkinElmer Inc.
- Bayer AG
- Abbott.
- Cipla Inc
- Teva Pharmaceutical Industries Ltd.
- Sanofi
- Johnson & Johnson Services, Inc.
- Dr. Reddy's Laboratories Ltd
- Almatica Pharma LLC.
- F. Hoffmann-La Roche Ltd
- GlaxoSmithKline Plc
- Eisen Pharmaceutical Co. (Pvt.) Ltd.
- Emcure Pharmaceuticals
- AbbVie.
- Sparsha Pharma International Pvt Ltd.
- Hope Medicine (Nanjing) Co., Ltd

"*" marked represents similar segmentation in other categories in the respective section.

Product Code: CMI5760

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Drug Class
- Market Snapshot, By Type
- Market Snapshot, By Route of administration
- Market Snapshot, By Dosage Form
- Market Snapshot, By Distribution channel
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Attractiveness Analysis
- Market Opportunities
Product Launches
Market Trends
Merger, Acquisition, Collaborations
Regulatory Guideline and Compliances
Key Developments
PEST Analysis
Technology Landscape
Pricing Analysis
Brand Analysis
Investments and Funding
Facility Expansions

4. Global Menstrual Cramps Treatment Market- Impact of Coronavirus (Covid-19) Pandemic

Government Initiatives
COVID-19 Epidemiology
Key Developments

5. Global Menstrual Cramps Treatment Market, By Drug Class, 2018-2030, (US$ Million)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018 - 2030
- Segment Trends
Analgesics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Million)
Anticholinergics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Million)
Non-steriodal anti-inflammatory drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Million)
Haematinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Million)
Others (Progestins, Among others)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Million)

6. Global Menstrual Cramps Treatment Market, By Type, 2018 - 2030, (US$ Million)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018 - 2030
- Segment Trends
Primary Dysmenorrhea
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Million)
Secondary Dysmenorrhea
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Million)

7. Global Menstrual Cramps Treatment Market, By Route of administration, 2018 - 2030, (US$ Million)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018 - 2030
- Segments Trends
Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Million)
Injectable
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Million)
Topical
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Million)
Others (Intrauterine, Among others)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Million)

8. Global Menstrual Cramps Treatment Market, By Dosage Form, 2018 - 2030, (US$ Million)

Tablet
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Million)
Capsules
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Million)
Suspension
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Million)
Others (Transdermal Patch, Among others)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Million)

9. Global Menstrual Cramps Treatment Market, By Distribution channel, 2018 - 2030, (US$ Million)

Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Million)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Million)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Million)

10. Global Menstrual Cramps Treatment Market, By Region, 2018 - 2030, (US$ Million)

Introduction
- Market Share Analysis, By Region, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, For Region, 2018-2030
- Regional Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2018 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of administration, 2018 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2018 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution channel, 2018 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 - 2030, (US$ Million)
U.S.
Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2018 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of administration, 2018 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2018 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution channel, 2018 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 - 2030, (US$ Million)
Brazil
Mexico
Argentina
Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2018 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of administration, 2018 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2018 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution channel, 2018 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 - 2030, (US$ Million)
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2018 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of administration, 2018 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2018 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution channel, 2018 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 - 2030, (US$ Million)
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2018 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of administration, 2018 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2018 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution channel, 2018 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 - 2030, (US$ Million)
GCC
Israel
Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2018 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of administration, 2018 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2018 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution channel, 2018 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 - 2030, (US$ Million)
North Africa
Central Africa
South Africa

11. Competitive Landscape

Pfizer, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Ingelheim International GmbH
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Bayer AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Abbott
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Cipla Inc
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Teva Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Sanofi
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Johnson & Johnson Services, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Reddy's Laboratories Ltd
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Almatica Pharma LLC.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
F. Hoffmann-La Roche Ltd
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
GlaxoSmithKline Plc
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Eisen Pharmaceutical Co. (Pvt.) Ltd
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Emcure Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
AbbVie
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Sparsha Pharma International Pvt Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Hope Medicine (Nanjing) Co., Ltd
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies

12. Section

Research Methodology
About Us

Have a question?

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Christine Sirois

Manager - Americas

+1-860-674-8796

SEE OUR FAQ